Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib.
Díaz-González Á, Sanduzzi-Zamparelli M, Sapena V, Torres F, LLarch N, Iserte G, Forner A, da Fonseca L, Ríos J, Bruix J, Reig M. Díaz-González Á, et al. Among authors: llarch n. Aliment Pharmacol Ther. 2019 Mar;49(5):482-491. doi: 10.1111/apt.15088. Epub 2019 Jan 29. Aliment Pharmacol Ther. 2019. PMID: 30695819
Pancreatic Insufficiency in Patients Under Sorafenib Treatment for Hepatocellular Carcinoma.
Díaz-González Á, Belmonte E, Sapena V, Sanduzzi-Zamparelli M, Darnell A, Díaz A, Gomes da Fonseca L, Llarch N, Iserte G, Ayuso C, Forner A, Feu F, Bruix J, Rimola J, Reig M. Díaz-González Á, et al. Among authors: llarch n. J Clin Gastroenterol. 2021 Mar 1;55(3):263-270. doi: 10.1097/MCG.0000000000001366. J Clin Gastroenterol. 2021. PMID: 32530871
Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials.
Díaz-González Á, Sapena V, Boix L, Brunet M, Torres F, LLarch N, Samper E, Millán O, Corominas J, Iserte G, Sanduzzi-Zamparelli M, da Fonseca LG, Darnell A, Belmonte E, Forner A, Ayuso C, Bruix J, Reig M. Díaz-González Á, et al. Among authors: llarch n. Liver Int. 2020 Oct;40(10):2476-2488. doi: 10.1111/liv.14587. Epub 2020 Jul 25. Liver Int. 2020. PMID: 33021346
Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma.
Corominas J, Sapena V, Sanduzzi-Zamparelli M, Millán C, Samper E, Llarch N, Iserte G, Torres F, Da Fonseca LG, Muñoz-Martínez S, Forner A, Bruix J, Boix L, Reig M. Corominas J, et al. Among authors: llarch n. Cancers (Basel). 2021 Jan 23;13(3):426. doi: 10.3390/cancers13030426. Cancers (Basel). 2021. PMID: 33498698 Free PMC article.
Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs.
Díaz-González Á, Sapena V, Boix L, Torres F, Sanduzzi-Zamparelli M, Da Fonseca LG, LLarch N, Iserte G, Guedes C, Muñoz-Martínez S, Darnell A, Belmonte E, Rimola J, Forner A, Ayuso C, Bruix J, Reig M. Díaz-González Á, et al. Among authors: llarch n. United European Gastroenterol J. 2021 Jul;9(6):655-661. doi: 10.1002/ueg2.12111. Epub 2021 Jul 6. United European Gastroenterol J. 2021. PMID: 34228394 Free PMC article.
16 results